Prevalence of Cefepime-Resistant Escherichia coli in Iran: A Meta-Analysis (2007-2016)
Background: Cefepime-resistant Escherichia coli (E. coli) is one of the seven important types of microbial resistance. This meta-analysis study was conducted to identify the prevalence of cefepime-resistant E. coli in Iran during 2007-2016.
Methods: Studies published were searched in Persian databases (including Magiran, and SID) and international databases (including PubMed, ScienceDirect, and Scopus). The selected studies included all types of laboratory methods. Moreover, the random effects model (DerSimonian Laird method) was used to addresses the high heterogeneity (50% < I2) between the reviewed studies. The collected data were categorized into different subgroups on the basis of the year of study and province. Data analysis was performed using the Statsdirect software.
Results: Overall, 516 articles were selected from the searched medical databases. After reviewing and applying the inclusion criteria, irrelevant papers were excluded and the remaining 26 studies were meta-analyzed. The overall prevalence of cefepime-resistant E. coli was 53.42% (95%: 43.35, 63.35), ranging from 25% (95%CI: 21.67, 28.55) in 2009 to 61.95% (95%CI: 56.62, 67.09) in 2016.
Conclusion: The prevalence of cefepime-resistant E. coli in Iran has had an increasing and alarming trend during the recent years. Therefore, it is necessary to use practical strategies and interventions to control and monitor cefepime-resistant E. coli in the country.
2. Planta MB(2007). The role of poverty in antimicrobial resistance. J Am Board Fam Med, 20(6):533-9.
3. Poirel L, Naas T, Guibert M, et al (1999). Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum β-lactamase encoded by an Escherichia coli integron gene. Antimicrob Agents Chemother, 43(3):573-81.
4. Lang AL, Tsai Y-L, Mayer CL, et al (1994). Multiplex PCR for detection of the heat-labile toxin gene and shiga-like toxin I and II genes in Escherichia coli isolated from natural waters. Appl Environ Microbiol, 60(9):3145-9.
5. Shlaes DM, Gerding DN, John Jr JF, et al (1997). Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis, 25(3):584-99.
6. Khalili H, Soltani R, Afhami S, et al (2012). Antimicrobial resistance pattern of Gram-negative bacteria of nosocomial origin at a teaching hospital in the Islamic Republic of Iran. East Mediterr Health J, 18(2):172-7.
7. Alam NH, Ashraf H (2003). Treatment of infectious diarrhea in children. Paediatr Drugs, 5(3):151-65.
8. Saeed M, Azarfar A, Bagheri S (2013). Streptococcus Pneumonia-Associated Hemolytic Uremic Syndrome: A Case Report. J Ped Nephrology, 1(2):82-84.
9. Svennerholm A-M, Tobias J (2008). Vaccines against enterotoxigenic Escherichia coli. Expert Rev Vaccines, 7(6):795-804.
10. Walker RI (2005). Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine, 23(26):3369-85.
11. Moradi G, Gouya MM, Eshrati B, et al (2018). National action plan of the Islamic Republic of Iran for combating antimicrobial resistance during 2016–2021. Med J Islam Repub Iran, 32:65
12. Murray CJ, Lopez AD, Organization WHO (1996). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Geneva : World Health Organization.
13. Morens DM, Fauci AS (2013). Emerging infectious diseases: threats to human health and global stability. PLoS Pathog, 9(7):e1003467.
14. Von Elm E, Altman DG, Egger M, et al (2014). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg, 12(12):1495-9.
15. Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med, 151(4):264-9.
16. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327(7414):557-60.
17. Lin J, Peng Y, Xu P, et al (2016). Methicillin-Resistant Staphylococcus aureus Nasal Colonization in Chinese Children: A Prevalence Meta-Analysis and Review of Influencing Factors. PLoS One, 11(7):e0159728.
18. Deng J, Wan C, Mu D, et al (2012). [Nasal carriage of community-acquired staphylococcus aureus and drug sensitivity tests in healthy children in Chengdu]. Si-chuan Da Xue Xue Bao Yi Xue Ban, 43(3):391-4. (in Chinese)
19. Higgins J, Thompson S, Deeks J, et al (2002). Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy, 7(1):51-61.
20. Najafi N, Alikhani A, Babamahmoudi F, et al (2013). Increased cefepime MIC for enterobacteriacae clinical isolates. Caspian J In-tern Med, 4(2):654-7.
21. Farajnia S, Alikhani MY, Ghotaslou R, et al (2009). Causative agents and antimicrobial susceptibilities of urinary tract infections in the northwest of Iran. Int J Infect Dis, 13(2):140-4.
22. Adib N, Ghanbarpour R, Solatzadeh H, et al (2014). Antibiotic resistance profile and virulence genes of uropathogenic Escherichia coli isolates in relation to phylogeny. Trop Biomed, 31(1):17-25.
23. Alikhani A, Babamahmoodi F, Foroutan Alizadegan L, et al (2015). Minimal inhibitory concentration of microorganisms causing surgical site infection in referral hospitals in North of Iran, 2011-2012. Caspian J Intern Med, 6(1):34-9.
24. Park YS, Adams-Haduch JM, Shutt KA, et al (2012). Clinical and Microbiologic Characteristics of Cephalosporin-Resistant Escherichia coli in Three Centers in the United States. Antimicrob Agents Chemother, 56(4):1870-6.
25. Hawser S, Bouchillon S, Lascols C, et al (2012). Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009). Clin Microbiol Infect, 18(3):253-9.
26. Bantar C, Famiglietti A, Goldberg M (2000). Three year surveillance study of nosocomial bacterial resistance in Argentina. Int J Infect Dis, 4(2):85-90.
27. Shakya P, Barrett P, Diwan V, et al (2013). Antibiotic resistance among Escherichia coli isolates from stool samples of children aged 3 to 14 years from Ujjain, India. BMC Infect Dis, 13:477.
28. Yang C-M, Lin M-F, Lin C-H, et al (2009). Characterization of antimicrobial resistance patterns and integrons in human fecal Escherichia coli in Taiwan. Jpn J Infect Dis, 62(3):177-81.
29. Chen Y, Chen X, Zheng S, et al (2014). Serotypes, genotypes and antimicrobial resistance patterns of human diarrhoeagenic Escherichia coli isolates circulating in southeastern China. Clin Mi-crobiol Infect, 20(1):52-8.
30. Yasir M, Ajlan AM, Shakil S, et al (2018). Molecular characterization, antimicrobial resistance and clinico-bioinformatics approaches to address the problem of extended-spectrum β-lactamase-producing Escherichia coli in western Saudi Arabia. Sci Rep, 8(1):14847.
31. Putnam S, Riddle M, Wierzba T, et al (2004). Antimicrobial susceptibility trends among Escherichia coli and Shigella spp. isolated from rural Egyptian paediatric populations with diarrhoea between 1995 and 2000. Clin Microbiol Infect, 10(9):804-10.
32. Bayram Y, Parlak M, Aypak C, et al (2013). Three-year review of bacteriological profile and antibiogram of burn wound isolates in Van, Turkey. Int J Med Sci, 10(1):19-23.
33. Miotto M, Ossai SA, Meredith JE, et al (2018). Genotypic and phenotypic characterization of Escherichia coli isolated from mollusks in Brazil and the United States. Microbiologyopen, e738.
34. Hackman HK, Brown CA, Twum-Danso K (2014). Antibiotic Resistance Profile of CTX-M-type Extended-Spectrum Beta-Lactamases in Escherichia coli and Klebsiella pneumoniae in Accra, Ghana. J Nat Sci Res, 4(12): 24-30.
Copyright (c) 2019 Iranian Journal of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.